Approximately 54% of 42 pediatric IBD patients treated with vedolizumab entered clinical remission within 14 weeks, even when prior treatment with anti-TNF-α drugs had failed, according to a retrospective multicenter study [7]. Here, TNF is linked to inflammatory bowel disease.